Tufts Center for the Study of Drug Development

About: Tufts Center for the Study of Drug Development is a based out in . It is known for research contribution in the topics: Drug development & Clinical trial. The organization has 78 authors who have published 258 publications receiving 16047 citations.

The new Dutch health insurance system and its implications for pharmaceutical innovation

Abstract: Purpose – The purpose of this paper is to provide commentary on the state of affairs regarding implementation of Dutch health insurance reform, focusing on whether such reform is conducive to pharmaceutical innovation.Design/methodology/approach – The general characteristics of the Dutch healthcare system is outlined, together with a brief synopsis of the 2006 health insurance reform initiative. This is followed by a description of the four market intervention mechanisms and their implications for pharmaceutical innovation. Finally, these implications and the potential for policy transfer to other European countries are discussed.Findings – The new Dutch health insurance system represents a novel approach that closely follows Enthoven's managed competition model. Certain features of the new system are conducive to pharmaceutical innovation. These positive features include more flexibility on the part of private insurers to deviate from the national formulary, speedier reimbursement appraisals, and more ea...

State of the industry for drug–diagnostic development: challenge and change on the path to precision medicine

Abstract: Four challenges to the adoption of personalized medicine were identified in the mid-2000s – adherence to the blockbuster model, the lack of a supportive regulatory environment, the dysfunctional payment system and physician barriers. In this article, we report on our study findings based on interviews with 24 senior executives from leading drug and diagnostics companies to assess progress made in addressing those challenges over the last decade. Overall, we found that even with payer pushback and adjusting to new business models, the majority of developers expected their business to increase over the next 5 years. Several factors that unexpectedly helped to shape the personalized medicine landscape, such as the growth of support in genomic medicine from the public sector, are also discussed.

The New Drug Approvals of 1993, 1994, & 1995: Trends in Drug Development

Abstract: Clinical Pharmacology & Therapeutics (1996) 59, 192–192; doi: 10.1038/sj.clpt.1996.267

Monoclonal antibodies as innovative anti-infective agents.

Abstract: Extract: Monoclonal antibodies (mAbs) are a thriving class of therapeutics with more than 150 products currently in clinical studies. Like antibodies made naturally in the human body, mAbs bind only to specific targets and can recruit elements of the immune system to destroy the targets. However, since the products are genetically engineered, mAbs can be designed to have characteristics suitable for a variety of medical needs. Since the products first entered clinical studies in the 1980s, commercial interest has focused on cancer and immunological disease treatments. Relatively few companies have used mAbs to target pathogens. The versatile nature of mAbs and the need for innovative medicines for infectious diseases, especially for those caused by newly emerging pathogens, should cause both the public and private sector to reconsider mAbs as anti-infective agents.